Simvastatin |
Tablet (Orally Disintegrating) |
II (Paddle) |
75 |
0.15% SDS Buffer, pH 6.8 |
900 |
5, 10, 15 and 30 |
2008/09/03 |
Siponimod Fumaric Acid |
Tablet |
II (Paddle) |
50 |
Phosphate Buffer, pH 6.8 with 0.1% (m/v) Polysorbate 80 |
900 mL [for 2 mg strength]
500 mL [for 0.25 mg strength] |
5, 10, 15, 20 and 30 |
2021/08/19 |
Sirolimus |
Gel |
|
|
Develop a method to characterize in vitro release |
|
|
2023/05/18 |
Sirolimus |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
Sitagliptin Phosphate |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
Sitagliptin Phosphate/Simvastatin |
Tablet |
II (Paddle) with stainless steel stationary quadrangular hanging basket |
100 |
10 mM Sodium phosphate buffer containing 1% Tween 80 with 50 μg/mL Butylated hydroxyanisole |
900 |
5, 10, 15, 20, 30, and 45 |
2013/10/31 |
Sodium Iodide I-123 |
Capsule |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
Sodium Iodide I-131 |
Capsule |
|
|
Develop a dissolution method |
|
|
2022/07/07 |
Sodium Oxybate |
For Suspension (Extended Release) |
II (Paddle) |
100 |
Stage 1: 0.1N HCl for 2h; Stage 2: pH 6.0 Phosphate Buffer for 6h |
900 |
0.25, 1, 2, 2.5, 3, 3.5, 4 and 5 hours |
2024/05/31 |
Sodium Phenylbutyrate |
Pellets |
II (Paddle) |
75 |
Simulated Intestinal Fluid without pancreatin |
900 |
5, 10, 15, 30 and 45 |
2024/02/05 |
Sodium Phenylbutyrate |
Powder for Oral |
II (Paddle) |
75 |
Simulated Intestinal Fluid |
900 |
15, 30, 45, 60 and 90 |
2009/04/02 |
Sodium Phenylbutyrate; Taurursodiol |
Powder |
II (Paddle) |
75 |
5 mM phosphate w/ 0.1% SDS, pH 6.8 |
900 |
5, 10, 15, 30 and 45 |
2024/02/05 |
Sodium Phosphate Dibasic Anhydrous/Sodium Phosphate Monobasic Monohydrate |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
Sofosbuvir |
Pellets |
II (Paddle) |
75 |
25 mM Potassium Phosphate Buffer, pH 5.5 |
900 |
5, 10, 15, 20, 30 and 45 |
2021/08/19 |
Sofosbuvir |
Tablet |
II (Paddle) |
75 |
0.05 M Phosphate Buffer, pH 6.8 |
900 |
5, 10, 15, 20 and 30 |
2021/08/19 |
Sofosbuvir/Velpatasvir |
Tablet |
II (Paddle) |
75 |
50 mM sodium acetate buffer,pH 5.0, with 0.5% w/v Cetyltrimethyl ammonium bromide (CTAB) |
900 |
5, 10, 15, 20 and 30 |
2016/10/20 |
Solifenacin Succinate |
Suspension |
II (Paddle) |
50 |
0.1 N HCl |
900 |
5, 10, 15, 20 and 30 |
2022/07/07 |
Solifenacin Succinate |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
Solriamfetol HCl |
Tablet |
I (Basket) |
100 |
0.1 N HCl |
900 |
5, 10, 15, 20 and 30 |
2021/08/19 |
Sonidegib Phosphate |
Capsule |
II (Paddle) with sinker |
75 |
Tier 1: 0.1 M HCl with 1.0% SDS; Tier II: Stage 1: 850 mL of 0.1 N HCl solution with pepsin [250’000 units/L]. Stage 2: After 10 minutes add 50 mL of 18% SDS in 0.1 N HCl |
Tier 1: 900; Tier 2: Stage 1: 850 mL, Stage 2: 900 mL |
15, 30, 45, 60, and 90 |
2016/03/17 |